Pharma BD Deal Intelligence
Skye Bioscience agreed to acquire the entire issued share capital of UK-based Redx Pharma via a scheme of arrangement under Part 26 of the UK Companies Act 2006. The all-share transaction is accompanied by concurrent financings of approximately $125 million committed by new and existing healthcare institutional investors; share consideration terms were not separately disclosed as a headline deal value. The combined company will trade on Nasdaq as Fibrx Therapeutics, led by the Redx management team and board, with lead program RXC008, a GI-restricted pan-ROCK inhibitor for fibrostenotic Crohn's disease carrying an open U.S. IND and FDA Fast Track designation. Topline Phase 2 data is expected in H2 2028. Both boards unanimously approved; close is expected in Q4 2026.
← Browse all deals · How we score deals
More: 2026 deals